A groundbreaking potential cure for sickle cell disease may soon emerge, focusing on genetic therapy using the CRISPR-Cas9 genome-editing system. This innovative treatment is aimed at alleviating the excruciating blood disorder and is currently undergoing rigorous evaluation by the US Food and Drug Administration (FDA) and its panel of experts.
Exploring Genetic Therapy for Sickle Cell Disease
On October 31, external advisors to the FDA convened to deliberate on a DNA-altering therapy targeting sickle-cell disease, a hereditary condition causing distorted red blood cells and severe pain. The advisers' primary focus during the meeting was the safety data submitted by Vertex Pharmaceuticals in Boston, Massachusetts, and CRISPR Therapeutics in Zug, Switzerland, the developers of the treatment.
"The paramount consideration here is safety," emphasized Dr. Mark Walters, a pediatrician at the UCSF Benioff Children's Hospital Oakland at the University of California, San Francisco. Dr. Walters has been part of the steering committee offering guidance on the clinical advancement of the treatment, known as exagamglogene autotemcel (exa-cel). He noted that the extent of safety data available will significantly influence the decision-making process.
Understanding Sickle Cell Disease
Sickle cell disease is a condition that affects hemoglobin, the protein responsible for carrying oxygen in red blood cells. A genetic mutation causes these cells to adopt a crescent shape, leading to blood flow blockages, excruciating pain, organ damage, and other complications.
This debilitating disease affects millions of people worldwide, with approximately 100,000 individuals in the United States alone. It is more prevalent in regions historically affected by malaria, such as Africa and India, and is commonly found in certain ethnic groups, including individuals of African, Middle Eastern, and Indian descent. Interestingly, scientists believe that carrying the sickle cell trait may offer protection against severe malaria.
Hope on the Horizon: New Treatments
Dr. Allison King, who specializes in caring for children and young adults with sickle cell disease, expressed her optimism regarding potential new treatments. She emphasized the importance of relieving the pain and health complications associated with this condition, describing it as "horribly painful," with some likening it to being "stabbed all over."
Current treatments involve medications and blood transfusions, with the only permanent solution being a bone marrow transplant from a closely matched donor, which carries the risk of rejection.
In contrast, the one-time gene therapy known as "exa-cel," developed by Vertex Pharmaceuticals and CRISPR Therapeutics, does not require a donor. Early results from clinical trials reported that, nine months after treatment, 31 out of 32 participants had not experienced a vaso-occlusive crisis. This is a significant improvement over their previous average of about four crises each year.
The goal of this therapy is to stimulate the body to revert to producing a fetal form of hemoglobin, which is naturally present at birth but typically switches to a defective adult form in individuals with sickle cell disease. The developers have described the treatment as "transformative" and emphasized its "strong safety profile."
Victoria Gray, the first patient to undergo this treatment, shared her experience, describing a life marked by severe pain and the relief she felt after receiving the gene therapy.
Concerns and Ongoing Research
CRISPR/Cas9 gene editing, a promising technology for treating genetic diseases like sickle cell disease, raises concerns about its potential cancer risks. One main worry is "off-target effects," where CRISPR/Cas9 may unintentionally alter genes other than the ones it's meant to, potentially causing unwanted genetic changes that could contribute to cancer development.
Another concern is the possibility of a DNA damage response mediated by the p53 pathway. When CRISPR-Cas9 creates double-strand breaks, it can lead to cell cycle arrest in cells with a functional p53 pathway, potentially favoring cells with impaired p53 function and increasing the cancer risk.
Efficiency in gene editing and the health of edited cells are also significant concerns. If the editing process is not efficient, it might limit CRISPR/Cas9's therapeutic potential, and changes in cell fitness could potentially contribute to cancer.
Additionally, the methods used to deliver CRISPR/Cas9 components into target cells pose challenges. Inefficient delivery may limit the treatment's effectiveness, and certain delivery methods could introduce additional risks, including immune responses and potential cancer-related issues. These concerns underscore the need for careful evaluation and safety measures in using CRISPR/Cas9 for medical purposes.
Challenges and Access to Treatment
Despite these concerns, the development of treatments like exa-cel should continue, as they offer hope for individuals with sickle cell disease. However, barriers such as the expected high cost of the therapy, potentially reaching $2 million per patient, and the complex nature of the treatment, which involves a bone marrow transplant and extended hospitalization, could limit access, both in the United States and in less affluent countries where the disease is prevalent.
Share This Post On
Leave a comment
You need to login to leave a comment. Log-in